

CYFARFOD BWRDD PRIFYSGOL IECHYD UNIVERSITY HEALTH BOARD MEETING

DYDDIAD Y CYFARFOD:	30 September 2021
DATE OF MEETING:	
TEITL YR ADRODDIAD:	Financial Report – Month 5 2021/22
TITLE OF REPORT:	
CYFARWYDDWR ARWEINIOL:	Huw Thomas, Director of Finance
LEAD DIRECTOR:	
SWYDDOG ADRODD:	Rebecca Hayes, Senior Finance Business Partner
REPORTING OFFICER:	

Pwrpas yr Adroddiad (dewiswch fel yn addas)

Purpose of the Report (select as appropriate)

Ar Gyfer Trafodaeth/For Discussion

ADRODDIAD SCAA SBAR REPORT

Sefyllfa / Situation

The purpose of this report is to outline the Health Board's financial position to date against our Annual Plan and assess the key financial projections, risks and opportunities for the financial year.

Asesiad / Assessment

The Health Board's Financial Plan is to deliver a deficit of £25.0m, after savings of £16.1m. This is following Welsh Government (WG) guidance to anticipate £32.4m of funding to non-recurrently offset the underlying position brought forward from 2020/21.

Month 5 Position

- The Month 5 Health Board financial position is an underspend of £0.1m against a deficit plan of £2.1m, after utilising £4.2m of WG funding for COVID-19, having offset £0.3m of cost reductions recognised due to reduced operational activity levels.

Projection

- Following confirmation of COVID-19 sustainability and programme funding from WG, the Health Board is forecasting to deliver the planned deficit of £25.0m. The risk to the in-year delivery is considered to be Low, recognising that the Health Board has limited risk of any significant increase in Workforce expenditure given the restricted supply, however this is predicated on receiving confirmation of WG funding in line with current guidance.
- The in-year gap between the savings target and identified savings schemes of £5.8m is partly mitigated by cost reductions resulting from COVID-19, with a remaining gap of £3.1m for which pipeline schemes require conversion to approved schemes. Of the identified schemes of £10.4m (of which £8.2m are Green), a significant number (£8.1m) are currently assessed as non-recurrent. Discussions are ongoing on the implications of this on our underlying deficit, given the significant risk of a deterioration from £57.4m in 2020/21 to £71.2m in 2021/22 if recurrent savings schemes of £13.8m are not identified in-year.

Savings

- Whilst the focus of the Health Board is on identifying and implementing recurrent schemes, the current combination of capacity and COVID-19 pressures being experienced operationally has diverted significant managerial resource which has meant that only £2.3m of recurrent plans of the required £16.m have been identified.
- The opportunities framework has identified schemes in excess of the in-year savings requirement, however these have not yet been converted into Amber/Green operational plans due to the escalating pressures caused by a lack of access to Primary Care manifesting in A&E attendances and Domiciliary and Social Care fragility preventing the discharge of medically fit patients. The implementation of plans to reduce the number of acute beds in this climate is exceptionally challenging.
- In-month delivery of £1.6m, which is £1.0m higher than the plan of identified savings schemes following the early delivery of a one-off rates rebate negotiation.
- The pipeline schemes are currently assumed to be delivered in the second half of the financial year.

Next Steps

- Continue to engage with partner organisations to develop plans to address the issues within the Primary Care and Social Care sectors, whilst working with operational teams to develop robust and deliverable recurrent saving schemes in line with the Health Board's Strategy and roadmap to financial sustainability.

Summary of key financial targets

The Health Board's key targets are as follows:

- Revenue: to contain the overspend within the Health Board's planned deficit
- Savings: to deliver savings plans to enable the revenue budget to be achieved
- Capital: to contain expenditure within the agreed limit
- PSPP: to pay 95% of Non-NHS invoices within 30 days of receipt of a valid invoice
- Cash: While there is no prescribed limit for cash held at the end of the month, WG encourages this to be minimised and a rule of thumb of 5% of monthly expenditure is used. For the Health Board, this is broadly £4.0m.

Key target		Annual limit	YTD limit	Actual delivery	Forecast Risk
Revenue	£'m	25.0	10.4	10.3	Low*
Savings	£'m	16.1	6.7	2.9	Medium
Capital	£'m	30.5	6.1	6.1	Low
Non-NHS PSPP	%	95.0	95.0	96.4	Low
Period end cash	£'m	4.0	4.0	3.4	Low

* The Health Board recognises that the risk against delivery of financial balance is high, and at this stage is reviewing all opportunities to reduce the revenue deficit in-year.

Argymhelliad / Recommendation

The Board is asked to discuss and note the financial position for Month 5.


Amcanion: (rhaid cwblhau) Objectives: (must be completed)	
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	1163 (score 12) Ability to deliver the Financial Plan for 2021/22 1199 (score 16) Achieving financial sustainability
Safon(au) Gofal ac Iechyd: Health and Care Standard(s):	5. Timely Care 7. Staff and Resources
Amcanion Strategol y BIP: UHB Strategic Objectives:	All Strategic Objectives are applicable
Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Statement	Improve Population Health through prevention and early intervention

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth: Evidence Base:	Monitoring returns to Welsh Government based on the Health Board's financial reporting system.
Rhestr Termau: Glossary of Terms:	<p>ADH – Additional Duty Hours BGH – Bronglais General Hospital CHC – Continuing Healthcare FYE – Full Year Effect GGH – Glangwili General Hospital GMS – General Medical Services LTAs – Long Term Agreements M&SE – Medical & Surgical Equipment MHLD – Mental Health & Learning Disabilities NICE – National Institute for Health and Care Excellence NOAC - Novel Oral Anti-Coagulant OOH – Out of Hours PPH – Prince Philip Hospital PSPP – Public Sector Payment Policy RSV - Respiratory Syncytial Virus RTT – Referral to Treatment Time SDEC – Same Day Emergency Care TB – Tuberculosis WG – Welsh Government WGH – Withybush General Hospital WRP – Welsh Risk Pool WHSSC – Welsh Health Specialised Services Committee YTD – Year to date</p>

Partïon / Pwyllgorau â ymgynhorwyd ymlaen llaw y pwylgor cyllid: Parties / Committees consulted prior to University Health Board:	Sustainable Resources Committee
---	---------------------------------

Effaith: (rhaid cwblhau) Impact: (must be completed)	
Ariannol / Gwerth am Arian: Financial / Service:	Financial impacts and considerations are inherent in the report.
Ansawdd / Gofal Claf: Quality / Patient Care:	These are assessed as part of our savings planning.
Gweithlu: Workforce:	The report discusses the impact of both variable pay and substantive pay.
Risg: Risk:	Financial risks are detailed in the report.
Cyfreithiol: Legal:	The Health Board has a legal duty to deliver a breakeven financial position over a rolling three-year basis and an administrative requirement to operate within its budget within any given financial year.
Enw Da: Reputational:	Adverse variance against the Health Board's financial plan will affect our reputation with Welsh Government, the Wales Audit Office, and with external stakeholders.
Gyfrinachedd: Privacy:	Not Applicable
Cydraddoldeb: Equality:	Not Applicable


Revenue Summary



Revenue Summary

YTD variance by Subjective (against Plan)		Key drivers of YTD position:
Pay	11.9	
Drugs	1.2	<ul style="list-style-type: none"> Pay (£11.9m): Primarily due to the fixed term staff recruited as part of the Health Board's response to COVID-19, but also includes increased premium agency requirement due to a high volume of vacancies, self isolation and sickness across Medical and Nursing posts and pressures on Emergency departments throughout the Health Board's Acute sites;
Clinical Supplies	1.3	<ul style="list-style-type: none"> Drugs & Clinical supplies (£2.5m): The overspend is primarily driven by the costs of PPE expenditure, home care drug regimes being provided to patients and sub-cutaneous to intravenous Cancer treatment (as a consequence of COVID-19) and Medicines Management pressures offset by reduced activity in elective services within Planned Care;
Income	0.4	<ul style="list-style-type: none"> Income (£0.4m): Income generated from NCA and RTA activity discussed above. There has also been a deterioration in income within Hospital sites due to lower patient numbers accessing commercial and hospitality facilities;
Premises & Plant	1.1	<ul style="list-style-type: none"> Primary Care (-£0.6m): Reduced level of claims from Ophthalmic contractors and Dental underperformance, offset by COVID-19 vaccinations carried out by GMS Contractors;
Primary Care	(0.6)	<ul style="list-style-type: none"> Prescribing (£0.6m): Pressures continue in Primary Care Prescribing due to continued increase in the cost per item for Category M and baseline drugs;
Prescribing	0.6	<ul style="list-style-type: none"> WG Funding (-£21.7m): Funding has been received from WG to offset the cost of the Health Board's response to the COVID-19 pandemic. This excludes the WG funding to offset the underlying position brought forward from 2020/21 in relation to undelivered savings, which is £13.5m YTD.
Commissioning	0.8	
Care packages	0.5	
Other	4.4	
Sub total	21.6	
COVID-19 WG Fund	(21.7)	
P05-22 Variance	(0.1)	
YTD actual by Subjective (COVID-19 only)		
Pay	11.4	
Drugs	0.8	
Clinical Supplies	1.0	
Income	1.2	
Premises & Plant	1.3	
Primary Care	1.0	
Prescribing	1.8	
Commissioning	1.1	
Care packages	0.7	
Other	4.0	
Total	24.3	

Subjective Summary





Pay costs have increased by £2.3m in-month. The main reason for this increase relates to retrospective payments made to staff in respect of the overtime during annual leave ruling of £2.1m.



Other drivers of the in-month pay movements are explained below:

- Substantive £0.8m:** A net increase in WTEs in-month due to higher numbers of Junior Doctors during the August intake, a net increase in Estates staff as part of the Health Board's COVID-19 response and a number of retrospective ADH claims being processed in-month;
- Agency Nursing £(0.8)m:** Due to the constrained availability of agency staff, expenditure reduced significantly as a number of shifts remained unfilled;
- Bank staff £(0.3)m:** The in-month reduction is driven by limited uptake during the school holidays and sickness absence;
- Overtime £0.3m:** Due to the Health Board's inability to fill shifts, a short term local increase in enhanced rates has been offered to staff. This assisted in securing those already rostered on overtime shifts in-month, however it has not yet been determined if the incentive increased or simply stabilised existing fill rates. A review will be undertaken at the end of September 2021.


Subjective Summary

CHC  <table border="1"><thead><tr><th>Date</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr></thead><tbody><tr><td>2020/21-01</td><td>4.8</td><td>4.2</td></tr><tr><td>2020/21-02</td><td>4.5</td><td>4.3</td></tr><tr><td>2020/21-03</td><td>4.2</td><td>4.2</td></tr><tr><td>2020/21-04</td><td>4.3</td><td>4.3</td></tr><tr><td>2020/21-05</td><td>4.1</td><td>4.1</td></tr><tr><td>2020/21-06</td><td>6.3</td><td>5.8</td></tr><tr><td>2020/21-07</td><td>4.2</td><td>4.5</td></tr><tr><td>2020/21-08</td><td>4.2</td><td>4.4</td></tr><tr><td>2020/21-09</td><td>4.4</td><td>4.5</td></tr><tr><td>2020/21-10</td><td>4.5</td><td>4.6</td></tr><tr><td>2020/21-11</td><td>4.7</td><td>4.8</td></tr><tr><td>2020/21-12</td><td>4.4</td><td>4.5</td></tr><tr><td>2021/22-01</td><td>4.2</td><td>4.3</td></tr><tr><td>2021/22-02</td><td>4.2</td><td>4.3</td></tr><tr><td>2021/22-03</td><td>4.7</td><td>4.6</td></tr><tr><td>2021/22-04</td><td>4.3</td><td>4.2</td></tr><tr><td>2021/22-05</td><td>4.2</td><td>4.1</td></tr><tr><td>2021/22-06</td><td>4.1</td><td>4.0</td></tr><tr><td>2021/22-07</td><td>4.2</td><td>4.1</td></tr><tr><td>2021/22-08</td><td>4.1</td><td>4.0</td></tr><tr><td>2021/22-09</td><td>4.1</td><td>4.0</td></tr><tr><td>2021/22-10</td><td>4.2</td><td>4.1</td></tr><tr><td>2021/22-11</td><td>4.1</td><td>4.1</td></tr><tr><td>2021/22-12</td><td>4.0</td><td>4.0</td></tr></tbody></table>	Date	Actual expenditure	Budgeted expenditure	2020/21-01	4.8	4.2	2020/21-02	4.5	4.3	2020/21-03	4.2	4.2	2020/21-04	4.3	4.3	2020/21-05	4.1	4.1	2020/21-06	6.3	5.8	2020/21-07	4.2	4.5	2020/21-08	4.2	4.4	2020/21-09	4.4	4.5	2020/21-10	4.5	4.6	2020/21-11	4.7	4.8	2020/21-12	4.4	4.5	2021/22-01	4.2	4.3	2021/22-02	4.2	4.3	2021/22-03	4.7	4.6	2021/22-04	4.3	4.2	2021/22-05	4.2	4.1	2021/22-06	4.1	4.0	2021/22-07	4.2	4.1	2021/22-08	4.1	4.0	2021/22-09	4.1	4.0	2021/22-10	4.2	4.1	2021/22-11	4.1	4.1	2021/22-12	4.0	4.0	Continuing Health Care expenditure has decreased by £0.1m compared to Month 4. Whilst the Health Board have seen a net increase of four patients in-month, the majority of these patients have been Funded Nursing Care clients. The additional costs of these packages have been offset with a reduction in high cost packages in Adult Mental Health and Community based Homecare.
Date	Actual expenditure	Budgeted expenditure																																																																										
2020/21-01	4.8	4.2																																																																										
2020/21-02	4.5	4.3																																																																										
2020/21-03	4.2	4.2																																																																										
2020/21-04	4.3	4.3																																																																										
2020/21-05	4.1	4.1																																																																										
2020/21-06	6.3	5.8																																																																										
2020/21-07	4.2	4.5																																																																										
2020/21-08	4.2	4.4																																																																										
2020/21-09	4.4	4.5																																																																										
2020/21-10	4.5	4.6																																																																										
2020/21-11	4.7	4.8																																																																										
2020/21-12	4.4	4.5																																																																										
2021/22-01	4.2	4.3																																																																										
2021/22-02	4.2	4.3																																																																										
2021/22-03	4.7	4.6																																																																										
2021/22-04	4.3	4.2																																																																										
2021/22-05	4.2	4.1																																																																										
2021/22-06	4.1	4.0																																																																										
2021/22-07	4.2	4.1																																																																										
2021/22-08	4.1	4.0																																																																										
2021/22-09	4.1	4.0																																																																										
2021/22-10	4.2	4.1																																																																										
2021/22-11	4.1	4.1																																																																										
2021/22-12	4.0	4.0																																																																										
Secondary Care Drugs  <table border="1"><thead><tr><th>Date</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr></thead><tbody><tr><td>2020/21-01</td><td>3.2</td><td>3.3</td></tr><tr><td>2020/21-02</td><td>2.9</td><td>3.0</td></tr><tr><td>2020/21-03</td><td>3.4</td><td>3.4</td></tr><tr><td>2020/21-04</td><td>3.8</td><td>3.7</td></tr><tr><td>2020/21-05</td><td>3.3</td><td>3.3</td></tr><tr><td>2020/21-06</td><td>4.7</td><td>4.6</td></tr><tr><td>2020/21-07</td><td>3.7</td><td>3.7</td></tr><tr><td>2020/21-08</td><td>3.9</td><td>3.8</td></tr><tr><td>2020/21-09</td><td>3.8</td><td>3.7</td></tr><tr><td>2020/21-10</td><td>3.9</td><td>3.8</td></tr><tr><td>2020/21-11</td><td>3.5</td><td>3.6</td></tr><tr><td>2020/21-12</td><td>3.9</td><td>3.8</td></tr><tr><td>2021/22-01</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-02</td><td>4.1</td><td>4.0</td></tr><tr><td>2021/22-03</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-04</td><td>4.1</td><td>4.0</td></tr><tr><td>2021/22-05</td><td>3.8</td><td>3.7</td></tr><tr><td>2021/22-06</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-07</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-08</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-09</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-10</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-11</td><td>3.7</td><td>3.6</td></tr><tr><td>2021/22-12</td><td>3.7</td><td>3.6</td></tr></tbody></table>	Date	Actual expenditure	Budgeted expenditure	2020/21-01	3.2	3.3	2020/21-02	2.9	3.0	2020/21-03	3.4	3.4	2020/21-04	3.8	3.7	2020/21-05	3.3	3.3	2020/21-06	4.7	4.6	2020/21-07	3.7	3.7	2020/21-08	3.9	3.8	2020/21-09	3.8	3.7	2020/21-10	3.9	3.8	2020/21-11	3.5	3.6	2020/21-12	3.9	3.8	2021/22-01	3.7	3.6	2021/22-02	4.1	4.0	2021/22-03	3.7	3.6	2021/22-04	4.1	4.0	2021/22-05	3.8	3.7	2021/22-06	3.7	3.6	2021/22-07	3.7	3.6	2021/22-08	3.7	3.6	2021/22-09	3.7	3.6	2021/22-10	3.7	3.6	2021/22-11	3.7	3.6	2021/22-12	3.7	3.6	Drug expenditure has decreased in-month by £0.2m. The majority of the decrease has been attributed to reduced activity in Oncology in month due to holidays and a reduction in homecare drug issues.
Date	Actual expenditure	Budgeted expenditure																																																																										
2020/21-01	3.2	3.3																																																																										
2020/21-02	2.9	3.0																																																																										
2020/21-03	3.4	3.4																																																																										
2020/21-04	3.8	3.7																																																																										
2020/21-05	3.3	3.3																																																																										
2020/21-06	4.7	4.6																																																																										
2020/21-07	3.7	3.7																																																																										
2020/21-08	3.9	3.8																																																																										
2020/21-09	3.8	3.7																																																																										
2020/21-10	3.9	3.8																																																																										
2020/21-11	3.5	3.6																																																																										
2020/21-12	3.9	3.8																																																																										
2021/22-01	3.7	3.6																																																																										
2021/22-02	4.1	4.0																																																																										
2021/22-03	3.7	3.6																																																																										
2021/22-04	4.1	4.0																																																																										
2021/22-05	3.8	3.7																																																																										
2021/22-06	3.7	3.6																																																																										
2021/22-07	3.7	3.6																																																																										
2021/22-08	3.7	3.6																																																																										
2021/22-09	3.7	3.6																																																																										
2021/22-10	3.7	3.6																																																																										
2021/22-11	3.7	3.6																																																																										
2021/22-12	3.7	3.6																																																																										

Subjective Summary

Clinical Supplies and Services  <table border="1"><thead><tr><th>Month</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr></thead><tbody><tr><td>2020/21-01</td><td>2.2</td><td>2.5</td></tr><tr><td>2020/21-02</td><td>2.1</td><td>2.4</td></tr><tr><td>2020/21-03</td><td>2.1</td><td>2.3</td></tr><tr><td>2020/21-04</td><td>2.1</td><td>2.4</td></tr><tr><td>2020/21-05</td><td>2.4</td><td>2.5</td></tr><tr><td>2020/21-06</td><td>4.8</td><td>3.8</td></tr><tr><td>2020/21-07</td><td>3.0</td><td>2.8</td></tr><tr><td>2020/21-08</td><td>3.5</td><td>3.2</td></tr><tr><td>2020/21-09</td><td>3.6</td><td>3.3</td></tr><tr><td>2020/21-10</td><td>3.6</td><td>3.4</td></tr><tr><td>2020/21-11</td><td>2.9</td><td>2.7</td></tr><tr><td>2020/21-12</td><td>4.7</td><td>4.0</td></tr><tr><td>2021/22-01</td><td>2.5</td><td>2.6</td></tr><tr><td>2021/22-02</td><td>2.5</td><td>2.6</td></tr><tr><td>2021/22-03</td><td>3.2</td><td>2.7</td></tr><tr><td>2021/22-04</td><td>3.3</td><td>2.7</td></tr><tr><td>2021/22-05</td><td>3.3</td><td>2.7</td></tr><tr><td>2021/22-06</td><td>2.5</td><td>2.5</td></tr><tr><td>2021/22-07</td><td>2.5</td><td>2.5</td></tr><tr><td>2021/22-08</td><td>2.5</td><td>2.5</td></tr><tr><td>2021/22-09</td><td>2.5</td><td>2.5</td></tr><tr><td>2021/22-10</td><td>2.5</td><td>2.5</td></tr><tr><td>2021/22-11</td><td>2.5</td><td>2.5</td></tr><tr><td>2021/22-12</td><td>2.5</td><td>2.5</td></tr></tbody></table>	Month	Actual expenditure	Budgeted expenditure	2020/21-01	2.2	2.5	2020/21-02	2.1	2.4	2020/21-03	2.1	2.3	2020/21-04	2.1	2.4	2020/21-05	2.4	2.5	2020/21-06	4.8	3.8	2020/21-07	3.0	2.8	2020/21-08	3.5	3.2	2020/21-09	3.6	3.3	2020/21-10	3.6	3.4	2020/21-11	2.9	2.7	2020/21-12	4.7	4.0	2021/22-01	2.5	2.6	2021/22-02	2.5	2.6	2021/22-03	3.2	2.7	2021/22-04	3.3	2.7	2021/22-05	3.3	2.7	2021/22-06	2.5	2.5	2021/22-07	2.5	2.5	2021/22-08	2.5	2.5	2021/22-09	2.5	2.5	2021/22-10	2.5	2.5	2021/22-11	2.5	2.5	2021/22-12	2.5	2.5	Expenditure in-month has remained flat in the month with sustained Acute pressures resulting in high usage of PPE, continued usage of an external diagnostics provider within the Radiology directorate due to a high level of staff vacancies and annual leave and continued M&SE maintenance and repairs within the Clinical engineering team.
Month	Actual expenditure	Budgeted expenditure																																																																										
2020/21-01	2.2	2.5																																																																										
2020/21-02	2.1	2.4																																																																										
2020/21-03	2.1	2.3																																																																										
2020/21-04	2.1	2.4																																																																										
2020/21-05	2.4	2.5																																																																										
2020/21-06	4.8	3.8																																																																										
2020/21-07	3.0	2.8																																																																										
2020/21-08	3.5	3.2																																																																										
2020/21-09	3.6	3.3																																																																										
2020/21-10	3.6	3.4																																																																										
2020/21-11	2.9	2.7																																																																										
2020/21-12	4.7	4.0																																																																										
2021/22-01	2.5	2.6																																																																										
2021/22-02	2.5	2.6																																																																										
2021/22-03	3.2	2.7																																																																										
2021/22-04	3.3	2.7																																																																										
2021/22-05	3.3	2.7																																																																										
2021/22-06	2.5	2.5																																																																										
2021/22-07	2.5	2.5																																																																										
2021/22-08	2.5	2.5																																																																										
2021/22-09	2.5	2.5																																																																										
2021/22-10	2.5	2.5																																																																										
2021/22-11	2.5	2.5																																																																										
2021/22-12	2.5	2.5																																																																										
Primary Care Prescribing  <table border="1"><thead><tr><th>Month</th><th>Actual expenditure</th><th>Budgeted expenditure</th></tr></thead><tbody><tr><td>2020/21-01</td><td>6.4</td><td>6.2</td></tr><tr><td>2020/21-02</td><td>5.8</td><td>5.6</td></tr><tr><td>2020/21-03</td><td>6.4</td><td>6.2</td></tr><tr><td>2020/21-04</td><td>6.5</td><td>6.3</td></tr><tr><td>2020/21-05</td><td>5.8</td><td>5.6</td></tr><tr><td>2020/21-06</td><td>8.3</td><td>8.1</td></tr><tr><td>2020/21-07</td><td>6.8</td><td>6.6</td></tr><tr><td>2020/21-08</td><td>6.4</td><td>6.2</td></tr><tr><td>2020/21-09</td><td>7.0</td><td>6.8</td></tr><tr><td>2020/21-10</td><td>6.4</td><td>6.2</td></tr><tr><td>2020/21-11</td><td>6.2</td><td>6.0</td></tr><tr><td>2020/21-12</td><td>8.8</td><td>7.8</td></tr><tr><td>2021/22-01</td><td>6.3</td><td>6.1</td></tr><tr><td>2021/22-02</td><td>6.1</td><td>5.9</td></tr><tr><td>2021/22-03</td><td>6.9</td><td>6.7</td></tr><tr><td>2021/22-04</td><td>6.9</td><td>6.7</td></tr><tr><td>2021/22-05</td><td>6.6</td><td>6.4</td></tr><tr><td>2021/22-06</td><td>6.7</td><td>6.5</td></tr><tr><td>2021/22-07</td><td>6.8</td><td>6.6</td></tr><tr><td>2021/22-08</td><td>6.8</td><td>6.6</td></tr><tr><td>2021/22-09</td><td>6.8</td><td>6.6</td></tr><tr><td>2021/22-10</td><td>6.6</td><td>6.4</td></tr><tr><td>2021/22-11</td><td>6.3</td><td>6.1</td></tr><tr><td>2021/22-12</td><td>6.8</td><td>6.6</td></tr></tbody></table>	Month	Actual expenditure	Budgeted expenditure	2020/21-01	6.4	6.2	2020/21-02	5.8	5.6	2020/21-03	6.4	6.2	2020/21-04	6.5	6.3	2020/21-05	5.8	5.6	2020/21-06	8.3	8.1	2020/21-07	6.8	6.6	2020/21-08	6.4	6.2	2020/21-09	7.0	6.8	2020/21-10	6.4	6.2	2020/21-11	6.2	6.0	2020/21-12	8.8	7.8	2021/22-01	6.3	6.1	2021/22-02	6.1	5.9	2021/22-03	6.9	6.7	2021/22-04	6.9	6.7	2021/22-05	6.6	6.4	2021/22-06	6.7	6.5	2021/22-07	6.8	6.6	2021/22-08	6.8	6.6	2021/22-09	6.8	6.6	2021/22-10	6.6	6.4	2021/22-11	6.3	6.1	2021/22-12	6.8	6.6	Prescribing costs has reduced by £0.4m in month as August has 1.0 fewer prescribing days than July.
Month	Actual expenditure	Budgeted expenditure																																																																										
2020/21-01	6.4	6.2																																																																										
2020/21-02	5.8	5.6																																																																										
2020/21-03	6.4	6.2																																																																										
2020/21-04	6.5	6.3																																																																										
2020/21-05	5.8	5.6																																																																										
2020/21-06	8.3	8.1																																																																										
2020/21-07	6.8	6.6																																																																										
2020/21-08	6.4	6.2																																																																										
2020/21-09	7.0	6.8																																																																										
2020/21-10	6.4	6.2																																																																										
2020/21-11	6.2	6.0																																																																										
2020/21-12	8.8	7.8																																																																										
2021/22-01	6.3	6.1																																																																										
2021/22-02	6.1	5.9																																																																										
2021/22-03	6.9	6.7																																																																										
2021/22-04	6.9	6.7																																																																										
2021/22-05	6.6	6.4																																																																										
2021/22-06	6.7	6.5																																																																										
2021/22-07	6.8	6.6																																																																										
2021/22-08	6.8	6.6																																																																										
2021/22-09	6.8	6.6																																																																										
2021/22-10	6.6	6.4																																																																										
2021/22-11	6.3	6.1																																																																										
2021/22-12	6.8	6.6																																																																										

Financial Projection



Key Assumptions

- The direct impact of COVID-19, including programme expenditure (in respect of mass vaccination programmes, Testing, Tracing, Enhanced Cleaning Standards, PPE, Adult Social Care Provider Support, and Long COVID-19 Service, RSV Paediatrics) is modelled up to a twelve-month scenario within the current forecast;
- All remaining COVID-19 related WG funding allocations are expected to be fully utilised in future months to offset the impact of COVID-19;
- Existing Services modelling assumes incremental reinstatement of elective services, approved Recovery Plans and Urgent Primary Care, however excludes both expenditure and any potential WG funding assumptions at present in relation to SDEC and other unapproved plans; once internal planning discussions are concluded the projection will be updated.

Assurance

- Improved assurance methods have been established, aligning to managers across the Health Board and the Regional Partnership Board.
- Performance monitored monthly through System Engagement meetings for the highest risk Directorates, from July including integrated Performance and Improving Together agenda.
- Following WG confirmation of, and guidelines for, COVID-19 stability and programme funding and funding to offset the underlying position brought forward from 2020/21, the Health Board is forecasting to deliver the planned deficit of £25.0m. The risk to the in-year delivery is considered to be Low, recognising that the Health Board has limited risk of any significant increase in Workforce expenditure given the restricted supply.

Concerns

- Discussions are ongoing on the implications of the significant risk of a deterioration in the underlying deficit from £57.4m in 2020/21 to £71.2m in 2021/22 if recurrent savings schemes of £13.8m are not identified in-year.

Next Steps

- Implement an Enhanced Bridging Service within the Health Board to assist the timely and appropriate discharge of patients until domiciliary care is available. Annual gross cost is c.£8m, which is not factored into the above forecast, with funding/recharge to be determined.
- Continue to engage with partner organisations to develop plans to address the issues within the Primary Care and Social Care sectors, whilst working with operational teams to develop robust and deliverable recurrent saving schemes in line with the Health Board's Strategy and roadmap to financial sustainability.
- Continually refine the analysis of the underlying deficit to provide an ongoing pipeline of opportunities for improvement for the Board.

Risks and Opportunities

Financial Risks	
£32.4m	WG guidance has been issued to the Health Board to assume £32.4m of non-recurrent WG funding to offset the underlying position brought forward from 2020/21 in relation to the savings gap. This is not yet confirmed and is subject to validation. Further, if this funding is not issued recurrently, this will significantly impact the underlying deficit.
£13.8m	The in-year gap between the savings target and identified savings schemes of £5.8m is partly mitigated by cost reductions resulting from COVID-19, with a remaining gap of £3.1m for which pipeline schemes require conversion to approved schemes. This follows the identification of £2.3m of new recurrent schemes in Month 5, in addition to the existing identified schemes of £8.1m, which are currently assessed as non-recurrent. Discussions are ongoing on the implications of this on our underlying deficit, given the significant risk of a deterioration if recurrent savings schemes of £13.8m are not identified in-year.
Opportunities	
	<p>The opportunities framework has identified schemes in excess of the in-year savings requirement, however these have not yet been converted into Amber/Green operational plans due to the operational pressures, mostly within Acute sites.</p> <p>The continued operational pressures within Unscheduled Care is placing risk on our ability to identify plans for the full £16.1m of recurrent savings (FYE) by 30th September 2021. Further, the escalating pressures caused by a lack of access to Primary Care manifesting in A&E attendances and Domiciliary and Social Care fragility preventing the discharge of medically fit patients. The implementation of plans to reduce the number of acute beds in this climate is exceptionally challenging. We are working with our Directorates to develop plans wherever possible based on the revised planning objective given to the Director of Operations.</p> <p>Any identified plans will need to be deliverable on a pro rata basis by the end of the financial year, ie. it is not currently expected that the in-year delivery would exceed the pipeline required to deliver a deficit of £25.m in the current year, but would evidence an achievable £16.1m or more in 2022/23 onwards.</p> <p>The current trend in Category M prices within Prescribing may lead to a further recurrent saving; these are declared quarterly, so is likely to be quantifiable in October 2021.</p>

Savings and turnaround actions

Risk-assessed directorate savings profile, delivery and forecast																																																																																	
<table border="1"><caption>Data for Risk-assessed directorate savings profile, delivery and forecast</caption><thead><tr><th>Month</th><th>Target Profile</th><th>Actual delivery</th><th>Low risk</th><th>Medium risk</th><th>Total</th></tr></thead><tbody><tr><td>2021/22-1</td><td>1,350</td><td>200</td><td>200</td><td>0</td><td>1,750</td></tr><tr><td>2021/22-2</td><td>1,350</td><td>200</td><td>200</td><td>0</td><td>1,750</td></tr><tr><td>2021/22-3</td><td>1,350</td><td>200</td><td>200</td><td>0</td><td>1,750</td></tr><tr><td>2021/22-4</td><td>1,350</td><td>580</td><td>580</td><td>0</td><td>1,750</td></tr><tr><td>2021/22-5</td><td>1,350</td><td>1,550</td><td>580</td><td>0</td><td>2,000</td></tr><tr><td>2021/22-6</td><td>1,350</td><td>0</td><td>550</td><td>0</td><td>1,350</td></tr><tr><td>2021/22-7</td><td>1,350</td><td>0</td><td>950</td><td>250</td><td>1,750</td></tr><tr><td>2021/22-8</td><td>1,350</td><td>0</td><td>850</td><td>350</td><td>1,750</td></tr><tr><td>2021/22-9</td><td>1,350</td><td>0</td><td>1,380</td><td>320</td><td>1,750</td></tr><tr><td>2021/22-10</td><td>1,350</td><td>0</td><td>900</td><td>350</td><td>1,750</td></tr><tr><td>2021/22-11</td><td>1,350</td><td>0</td><td>880</td><td>370</td><td>1,750</td></tr><tr><td>2021/22-12</td><td>1,350</td><td>0</td><td>850</td><td>400</td><td>1,750</td></tr></tbody></table>				Month	Target Profile	Actual delivery	Low risk	Medium risk	Total	2021/22-1	1,350	200	200	0	1,750	2021/22-2	1,350	200	200	0	1,750	2021/22-3	1,350	200	200	0	1,750	2021/22-4	1,350	580	580	0	1,750	2021/22-5	1,350	1,550	580	0	2,000	2021/22-6	1,350	0	550	0	1,350	2021/22-7	1,350	0	950	250	1,750	2021/22-8	1,350	0	850	350	1,750	2021/22-9	1,350	0	1,380	320	1,750	2021/22-10	1,350	0	900	350	1,750	2021/22-11	1,350	0	880	370	1,750	2021/22-12	1,350	0	850	400	1,750
Month	Target Profile	Actual delivery	Low risk	Medium risk	Total																																																																												
2021/22-1	1,350	200	200	0	1,750																																																																												
2021/22-2	1,350	200	200	0	1,750																																																																												
2021/22-3	1,350	200	200	0	1,750																																																																												
2021/22-4	1,350	580	580	0	1,750																																																																												
2021/22-5	1,350	1,550	580	0	2,000																																																																												
2021/22-6	1,350	0	550	0	1,350																																																																												
2021/22-7	1,350	0	950	250	1,750																																																																												
2021/22-8	1,350	0	850	350	1,750																																																																												
2021/22-9	1,350	0	1,380	320	1,750																																																																												
2021/22-10	1,350	0	900	350	1,750																																																																												
2021/22-11	1,350	0	880	370	1,750																																																																												
2021/22-12	1,350	0	850	400	1,750																																																																												
<p>Assurance</p> <ul style="list-style-type: none">The in-year gap between the savings target and identified savings schemes of £5.8m is partly mitigated by cost reductions resulting from COVID-19, with a remaining gap of £3.1m for which pipeline schemes require conversion to approved schemes. This follows the identification of £2.3m of new recurrent schemes in Month 5. The identified schemes of £10.4m (of which £8.2m are Green), are assessed as low risk of non-delivery.In-month delivery of £1.6m, which is £1.0m higher than the plan of identified savings schemes following the early delivery of a one-off rates rebate negotiation.		<p>Concerns</p> <ul style="list-style-type: none">The unprecedented circumstances mean that operational focus is diverted to the organisation's response to COVID-19, and therefore not on the delivery or identification of the required level or of recurrent savings schemes that are not supportive of the response to the pandemic. Further, the escalating pressures caused by a lack of access to Primary Care manifesting in A&E attendances and Domiciliary and Social Care fragility preventing the discharge of medically fit patients. The implementation of plans to reduce the number of acute beds in this climate is exceptionally challenging.Discussions are ongoing for additional funding to support the non-delivery of the Health Board's brought forward savings target from FY21 on a recurrent basis, having received guidance that non-recurrent support will be provided in-year (subject to validation at this stage).	<p>Next Steps</p> <ul style="list-style-type: none">The opportunities framework has identified schemes in excess of the in-year savings requirement, however these have not yet been converted into Amber/Green operational plans due to the operational pressures, mostly within Acute sites.The continued operational pressures within Unscheduled Care is placing risk on our ability to identify plans for the full £16.1m of recurrent savings (FY21) by 30th September 2021. We are working with our Directorates to develop plans wherever possible based on the revised planning objective given to the Director of Operations.																																																																														